Identification | Back Directory | [Name]
3-Pyridinecarboxamide, 5-(3,4-dichlorophenyl)-N-[(1R,2R)-2-hydroxycyclohexyl]-6-(2,2,2-trifluoroethoxy)- | [CAS]
1269826-44-9 | [Synonyms]
OSBPL7-IN-1 3-Pyridinecarboxamide, 5-(3,4-dichlorophenyl)-N-[(1R,2R)-2-hydroxycyclohexyl]-6-(2,2,2-trifluoroethoxy)- | [Molecular Formula]
C20H19Cl2F3N2O3 | [MOL File]
1269826-44-9.mol | [Molecular Weight]
463.28 |
Chemical Properties | Back Directory | [Boiling point ]
540.9±50.0 °C(Predicted) | [density ]
1.46±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
5.98±0.40(Predicted) | [color ]
White to off-white |
Hazard Information | Back Directory | [Biological Activity]
OSBPL7-IN-1 is an orally active oxysterol binding protein like 7 (OSBPL7) inhibitor. OSBPL7-IN-1 promotes an increase of ABCA1 at the plasma membrane without affecting mRNA expression[1].
OSBPL7-IN-1 (compound G or Cpd G; 1-10 μM) increase plasma membrane ATP-binding cassette transporter (ABCA1) in cultured human podocytes, and significantly increase ABCA1-dependent cholesterol efflux[1].
OSBPL7-IN-1 (100 mg/kg; oral gavage; daily; for 28 days) treatment normalizes proteinuria and prevents renal function decline in mouse models of proteinuric kidney disease[1]. | [References]
[1]. Matthew B Wright, et al. Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux preserving kidney function in two models of kidney disease. Nat Commun. 2021 Aug 2;12(1):4662. |
|
|